Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Colorectal Neoplasms 10Breast Neoplasms 9Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Adenomatous Polyposis Coli 4Sarcoma 3Glioblastoma 3Central Nervous System Neoplasms 3Paranasal Sinus Neoplasms 2Neoplasms 2Mouth Neoplasms 2Melanoma 2Laryngeal Neoplasms 2Gliosarcoma 2Breast Carcinoma In Situ 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Tobacco Use Disorder 1Stomatitis 1Smoldering Multiple Myeloma 1Smoking 1Recurrence 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Precancerous Conditions 1

Interventions

Cisplatin 3Radiotherapy 2Hydroxyurea 2Fluorouracil 2Erlotinib Hydrochloride 2Drug Therapy 2Cetuximab 2pembrolizumab 1Radiotherapy, Intensity-Modulated 1Docetaxel 1Chemoradiotherapy 1Celecoxib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pharyngeal Neoplasms × Celecoxib × Clear all
NCT00970502 2017-04-10

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
15 enrolled 16 charts
Head & Neck

Head and Neck Neoplasms, Laryngeal Neoplasms, Paranasal Sinus Neoplasms, Pharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡